Ophthotech Corp (NASDAQ:OPHT) CEO Glenn Sblendorio sold 8,089 shares of Ophthotech stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total transaction of $25,803.91. Following the completion of the transaction, the chief executive officer now directly owns 44,584 shares in the company, valued at approximately $142,222.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ophthotech Corp (OPHT) traded up $0.03 during midday trading on Wednesday, hitting $3.30. 361,437 shares of the stock were exchanged, compared to its average volume of 558,700. Ophthotech Corp has a 12 month low of $2.24 and a 12 month high of $5.25. The firm has a market capitalization of $118.93, a P/E ratio of 2.12 and a beta of 1.58.

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Manhattan Co. acquired a new stake in shares of Ophthotech in the third quarter valued at approximately $1,201,000. Goldman Sachs Group Inc. raised its holdings in shares of Ophthotech by 28.1% in the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after purchasing an additional 143,349 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in shares of Ophthotech by 1.7% in the second quarter. Stonepine Capital Management LLC now owns 3,576,189 shares of the biopharmaceutical company’s stock valued at $9,155,000 after purchasing an additional 59,700 shares during the last quarter. Federated Investors Inc. PA raised its holdings in shares of Ophthotech by 102.3% in the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 28,040 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Ophthotech by 73.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 49,928 shares during the last quarter. Institutional investors own 62.48% of the company’s stock.

OPHT has been the topic of a number of research reports. ValuEngine raised shares of Ophthotech from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. TheStreet upgraded shares of Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 price objective on shares of Ophthotech in a report on Thursday, September 21st. Finally, Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective on the stock in a report on Monday, November 13th.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/03/glenn-sblendorio-sells-8089-shares-of-ophthotech-corp-opht-stock.html.

About Ophthotech

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.